Innovative Vaccine Development CEPI's focus on accelerated vaccine development, particularly the 100 Days Mission, presents opportunities for collaboration with biotech companies and suppliers specializing in rapid manufacturing technologies and biologics production.

Strategic Partnerships Recent collaborations with Samsung, Merck, and Seoul National University highlight CEPI's openness to engaging with technology firms, research institutions, and vaccine manufacturers, creating avenues for providing advanced R&D solutions and contract research services.

Funding and Growth Potential With a revenue range of 25 to 50 million dollars and active global funding initiatives, CEPI offers prospects for donors and sponsors in public health, biotech, and pharmaceuticals to support or expand their involvement in epidemic preparedness projects.

Emerging Vaccine Portfolio CEPI’s work on developing vaccines for Ebola, Marburg, Lassa Fever, and SFTS suggests opportunities for vendors in vaccine formulation, distribution logistics, and clinical trial management tailored to infectious disease outbreaks.

Global Health Engagements CEPI’s partnerships with international organizations and regional health agencies in Africa and Asia open pathways for international supply chain providers, clinical service providers, and technology vendors focused on global health initiatives.